Table 1. Summary of clinicopathological features.
| ID | Age (years) | Type | Level of lymphocytic infiltration a | CD45 (%) | Size (cm) | HG | NG | Mitosis | OG | LVI | LN | ER | PR | HER2 | FISH |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 40 | IDC NOS | Moderate | 36.6 | 2 | 3 | 3 | 3 | 3 | No | No | 0 | 0 | 0 | — |
| 2 | 72 | IDC NOS | Moderate | 11.89 | 1.5 | 3 | 3 | 3 | 3 | No | No | 0 | 0 | 0 | — |
| 3b | 37 | IDC NOS | Extensive | 12.5 | 4.5 | 3 | 3 | 3 | 3 | No | No | <1% | <1% | 1+ to 2+ | 1.3 |
| 4 | 35 | IDC NOS | Moderate | 0.4 | 5 | 2 | 3 | 3 | 3 | Yes | Yes | 95% | 90% | 3+ | — |
| 5 | 64 | ILC (C/P) | Minimal | 5.0 | 1 | 3 | 3 | 1 | 2 | No | No | 99% | 10% | 1+ | — |
| 6 | 62 | Apocrine | Moderate | 0.6 | 3.3 | 2 | 3 | 2 | 2 | Yes | Yes | 0 | 0 | 0 | — |
| 7 | 83 | IDC NOS | Moderate | 1.4 | 3.1 | 3 | 3 | 2 | 3 | Yes | No | 0 | 0 | 0 | — |
| 8 | 35 | IDC NOS | Moderate | 19.1 | 2.3 | 3 | 3 | 3 | 3 | No | No | 0 | 0 | 0 | — |
| 9 | 39 | IDC NOS | Extensive | 40.95 | 3 | 3 | 3 | 3 | 3 | No | No | 0 | 0 | 1+ | — |
| 10 | 62 | IDC NOS | Moderate | 7.6 | 1.8 | 3 | 3 | 3 | 3 | Yes | No | 0 | 0 | 1+ | — |
| 11c | 53 | IDC NOS | Minimal | 0.7 | 1.9 | 3 | 3 | 2 | 3 | No | NA | 0 | 0 | 1+ | — |
| 12 | 88 | Mucinous | Moderate | 0.3 | 6.6 | 2 | 1 | 1 | 1 | No | Yes | 95% | 60% | 0 | — |
| 13 | 56 | IDC NOS | Moderate | 1.4 | 2.5 | 3 | 3 | 3 | 3 | Yes | No | 5% | 5% | 3+ | — |
| 14 | 65 | IDC NOS | Minimal | 1 | 2.1 | 3 | 3 | 3 | 3 | Yes | NA | 0 | 5% | 1+ | — |
| 15 | 72 | IDC NOS | Moderate | 3 | 1.3 | 3 | 3 | 3 | 3 | No | No | 0 | 0 | 0 | — |
Abbreviations: ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HG, histological grade; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node involvement; LVI, lymphovascular invasion; NA, not sampled; NG, nuclear grade; NOS, not otherwise specified; PR, progesterone receptor; TIL, tumor-infiltrating lymphocyte; OG, overall grade.
a
Scoring criteria for the level of lymphocytic infiltration are defined in PATIENTS AND METHODS.
b
Patient with concurrent astrocytoma (WHO III).
c
Ipsilateral breast cancer recurrence.